News & Updates
Filter by Specialty:
Oral testosterone undecanoate safe, effective in hypogonadal men
15 Dec 2022
Long-term treatment with an oral testosterone undecanoate (TU) formulation improves clinical outcomes in men with hypogonadism with no serious safety concerns, a study has shown.
Oral testosterone undecanoate safe, effective in hypogonadal men
15 Dec 2022
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
13 Dec 2022
byChristina Lau
A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
13 Dec 2022
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022
byStephen Padilla
In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.
